Movement Alert｜HANSOH PHARMA Rises 3.6% in Regular Trading, New Drug HS-10582 Receives NMPA Clinical Trial Approval

Market Focus

Aug 07

On August 7, HANSOH PHARMA rose 3.6% in regular trading, trading at HK$32.82/share, with turnover of HK$330 million. The gain was driven by news that the company's self-developed Class 1 new drug HS-10582 tablet received a clinical trial approval notice from China's National Medical Products Administration (NMPA).

According to company filings dated August 6, HS-10582 is intended for clinical trials in the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, marking a new addition to Hansoh's cardiovascular-metabolic pipeline. The board stated that clinical trials will proceed in accordance with regulatory requirements, with progress to be disclosed in due course.

The approval follows a series of recent pipeline milestones, including the Phase 3 success of HS-20093 in both osteosarcoma and small cell lung cancer, as well as clinical trial approvals for HS-20136-2 injection in type 2 diabetes and weight management. CLSA recently maintained an Outperform rating with a raised target price of HK$42, forecasting five new drug approvals for Hansoh next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1151659831"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151659831\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151659831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 15:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151659831","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Rises 3.6% in Regular Trading, New Drug HS-10582 Receives NMPA Clinical Trial Approval","media":"Market Focus","content":"<p><p>On August 7, HANSOH PHARMA rose 3.6% in regular trading, trading at HK$32.82/share, with turnover of HK$330 million. The gain was driven by news that the company's self-developed Class 1 new drug HS-10582 tablet received a clinical trial approval notice from China's National Medical Products Administration (NMPA).</p><p>According to company filings dated August 6, HS-10582 is intended for clinical trials in the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, marking a new addition to Hansoh's cardiovascular-metabolic pipeline. The board stated that clinical trials will proceed in accordance with regulatory requirements, with progress to be disclosed in due course.</p><p>The approval follows a series of recent pipeline milestones, including the Phase 3 success of HS-20093 in both osteosarcoma and small cell lung cancer, as well as clinical trial approvals for HS-20136-2 injection in type 2 diabetes and weight management. CLSA recently maintained an Outperform rating with a raised target price of HK$42, forecasting five new drug approvals for Hansoh next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Rises 3.6% in Regular Trading, New Drug HS-10582 Receives NMPA Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Rises 3.6% in Regular Trading, New Drug HS-10582 Receives NMPA Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 15:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, HANSOH PHARMA rose 3.6% in regular trading, trading at HK$32.82/share, with turnover of HK$330 million. The gain was driven by news that the company's self-developed Class 1 new drug HS-10582 tablet received a clinical trial approval notice from China's National Medical Products Administration (NMPA).</p><p>According to company filings dated August 6, HS-10582 is intended for clinical trials in the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, marking a new addition to Hansoh's cardiovascular-metabolic pipeline. The board stated that clinical trials will proceed in accordance with regulatory requirements, with progress to be disclosed in due course.</p><p>The approval follows a series of recent pipeline milestones, including the Phase 3 success of HS-20093 in both osteosarcoma and small cell lung cancer, as well as clinical trial approvals for HS-20136-2 injection in type 2 diabetes and weight management. CLSA recently maintained an Outperform rating with a raised target price of HK$42, forecasting five new drug approvals for Hansoh next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1151659831","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151659831","pubTimestamp":1786089432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, HANSOH PHARMA rose 3.6% in regular trading, trading at HK$32.82/share, with turnover of HK$330 million. The gain was driven by news that the company's self-developed Class 1 new drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"异动提醒|豪森制药常规交易涨3.6%，新药HS-10582获NMPA临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On August 7, HANSOH PHARMA rose 3.6% in regular trading, trading at HK$32.82/share, with turnover of HK$330 million. The gain was driven by news that the company's self-developed Class 1 new drug HS-10582 tablet received a clinical trial approval notice from China's National Medical Products Administration (NMPA).According to company filings dated August 6, HS-10582 is intended for clinical trials in the treatment of adult primary hypercholesterolemia and mixed dyslipidemia, marking a new addition to Hansoh's cardiovascular-metabolic pipeline. The board stated that clinical trials will proceed in accordance with regulatory requirements, with progress to be disclosed in due course.The approval follows a series of recent pipeline milestones, including the Phase 3 success of HS-20093 in both osteosarcoma and small cell lung cancer, as well as clinical trial approvals for HS-20136-2 injection in type 2 diabetes and weight management. CLSA recently maintained an Outperform rating with a raised target price of HK$42, forecasting five new drug approvals for Hansoh next year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}